- Home
- NAMS vs PGEN Comparison
NAMS vs PGEN Comparison
Compare NAMS & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NAMS | PGEN |
|---|---|---|
| Founded | 2019 | 1998 |
| Country | Netherlands | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.8B |
| IPO Year | 2022 | 2013 |
Fundamental Metrics
Financial Performance| Metric | NAMS | PGEN |
|---|---|---|
| Price | $20.60 | $4.67 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 16 | 4 |
| Target Price | ★ $50.22 | $14.00 |
| AVG Volume (30 Days) | 1.6M | ★ 7.1M |
| Earning Date | 11-04-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.81 | N/A |
| EPS | N/A | ★ 0.12 |
| Revenue | $22,503,000.00 | ★ $230,981,000.00 |
| Revenue This Year | $91.66 | $2,335.22 |
| Revenue Next Year | $62.38 | $85.34 |
| P/E Ratio | ★ N/A | $37.79 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $17.90 | $3.04 |
| 52 Week High | $42.21 | $8.98 |
Technical Indicators
Market Signals| Indicator | NAMS | PGEN |
|---|---|---|
| Relative Strength Index (RSI) | 49.33 | 36.60 |
| Support Level | $19.36 | $3.50 |
| Resistance Level | $22.28 | $5.75 |
| Average True Range (ATR) | 1.38 | 0.47 |
| MACD | 0.08 | -0.13 |
| Stochastic Oscillator | 60.55 | 26.57 |
Price Performance
Historical ComparisonAbout NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.
About PGEN Precigen Inc.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.